CommercialCoverageMedium impact
Hematopoietic Cell Transplantation for Testicular Cancer (CPB 0617, reviewed 2025-12-03)
Aetna·Oncology, Hematology, Urology·Medical Policy
Effective date
Dec 3, 2025
We identified it
Aug 17, 2026
Summary
Aetna's updated policy (CPB 0617, effective 2025-12-03) clarifies coverage for hematopoietic cell transplantation in testicular cancer. Autologous HCT is now covered for refractory disease, relapsed disease, and tandem transplantation when criteria are met, but remains non-covered for initial treatment or allogeneic transplantation. Billing teams must ensure claims align with these specific clinical scenarios to avoid denials.
Action Required
By 2025-12-03: Billing team must update authorization and claims processing workflows for testicular cancer HCT claims. (1) Flag and require prior authorization review for CPT codes 38206, 38230, 38241, 96401-96549, and HCPCS S2150 when billed with ICD-10 codes C62.00-C62.92 or D07.69. (2) Ensure billing system validates that autologous HCT claims include documentation of one of the three covered scenarios: refractory disease (less than 50% tumor burden reduction), partial response (at least 50% reduction), relapsed disease after initial chemotherapy, or tandem transplantation for relapsed disease. (3) Update claim denial rules to automatically reject any claims for allogeneic HCT (CPT 38240, 38205, HCPCS codes with allogeneic descriptor) with reason code indicating non-covered service. (4) Train billing staff and providers that autologous HCT as initial treatment (instead of standard-dose chemotherapy) remains experimental/non-covered and will be denied. (5) Implement pre-authorization checklist requiring clinical documentation of: initial chemotherapy response status, tumor burden reduction percentage, and whether patient meets refractory/relapsed/tandem criteria. Failure to obtain prior authorization and validate medical necessity will result in claim denials.